Therefore, molecular targeted therapies, including combinations of BRAF inhibitors with mitogen‐activated protein kinase kinase (MEK) inhibitors, as well as immunotherapies like Janus kinase (JAK) inhibitors and Tyrosine kinase inhibitors (TKIs), have shown efficacy in treating anaplastic thyroid carcinoma (ATC). Here, MAP2K7 is linked to thyroid gland undifferentiated (anaplastic) carcinoma.